Journal: Clinical and Translational Medicine
Article Title: β‐elemene promotes ferroptosis to improve the sensitivity of imatinib in gastrointestinal stromal tumours by targeting N6AMT1
doi: 10.1002/ctm2.70438
Figure Lengend Snippet: β‐elemene targets N6AMT1 to promote imatinib sensitivity in imatinib‐resistant GIST cells via the nuclear factor erythroid 2‐related factor 2 (NRF2)/HMOX1 axis. (A) The workflow for cellular targets identification of β‐elemene in GIST‐T1‐IR by thermal proteome profiling (TPP). (B) Heatmap of differentially expressed protein in GIST‐T1‐IR cells between control and β‐elemene‐treated groups. (C) Venn diagram of β‐elemene target screening. (D) Volcano plot of cellular targets of β‐elemene by the TPP strategy. (E) Western blot analysis of NRF2 and HMOX1 in GIST cells with or without N6AMT1 knockdown by small interfering RNA (siRNA). (F) Western blot analysis of NRF2 and HMOX1 in GIST cells with or without N6AMT1 overexpression. (G) Cellular thermal shift assay demonstrated a stabilisation effect of N6AMT1 with β‐elemene. (H) The interaction between β‐elemene with N6AMT1 targeting Asp103 was predicted by molecular docking. (I) GIST‐T1‐IR cell lysates were incubated with either biotin or β‐elemene‐biotin at 4°C overnight, and then a pulldown assay was performed. (J) GIST‐T1‐IR cell lysates were preincubated with either DMSO or free β‐elemene, followed by subsequent incubation with β‐elemene‐biotin. The interaction between N6AMT1 and β‐elemene was then detected by capturing β‐elemene‐biotin. (K) The mutant N6AMT1 proteins were incubated with β‐elemene, followed by protein affinity pull‐down assay and detected by immunoblotting. (L) Western blot analysis of N6AMT1/NRF2/HMOX1 axis in GIST cells treated with imatinib, β‐elemene or imatinib+β‐elemene. (M) Western blot analysis of NRF2 in cytosol protein and nuclear protein. (N) The staining intensity and localisation of NRF2 in the indicated groups were analysed by immunofluorescence staining. (O) Western blot analysis of the relationship of NRF2 and HMOX1 in ferroptosis with knockdown of NRF2 in GIST cells followed by imatinib+β‐elemene treatment. (P) Methylation level of NRF2 promoter in GIST‐T1‐IR cell treated with imatinib, β‐elemene or imatinib+β‐elemene. (Q) Methylation level of NRF2 promoter in GIST‐T1‐IR cell with or without N6AMT1 knockdown by siRNA. (R) Methylation level of NRF2 promoter in GIST‐T1‐IR cell with or without N6AMT1 overexpression. Data represent the mean ± SD; * p < .05; ** p < .01; *** p < .001. An unpaired t ‐test was used unless otherwise stated.
Article Snippet: All cell lines were cultured in an incubator with 37 ° C and 5% CO 2 . β‐elemene was provided by Dalian HolleyKingkong Pharmaceutical Co. Ltd. Imatinib (T6230) was purchased from TargetMol.
Techniques: Control, Western Blot, Knockdown, Small Interfering RNA, Over Expression, Thermal Shift Assay, Incubation, Mutagenesis, Pull Down Assay, Staining, Immunofluorescence, Methylation